好！
孙榕表示，本次合成生物与生物制造论坛是沙利文二十届全球增长、科创与领导力峰会体系中，首次独立开设的以合成生物学为主题的专属论坛，意义特殊、价值深远。论坛的成功落地，承载着沙利文研究团队长期深耕于该赛道的深厚积淀，例如《上海合成生物与生物制造产业发展白皮书（2025）》等一系列专项研究成果，沉淀了对全球产业变革、技术迭代、产品落地痛点、投融资趋势等的深度洞察经验，将多年的静态研究数据、产业研判经验，转化为本次动态、开放、高效、全链式的交流平台，可以说，本次盛会是沙利文长期深耕生物制造赛道、持续赋能产业发展的一次集中成果呈现。
01
开场致辞
国家生物制造产业创新中心总经理罗巍先生为论坛作开幕致辞。
沙利文中国主管合伙人兼总裁、头豹联合创始人兼总裁王晨晖先生在致辞中回顾了沙利文持续跟踪全球合成生物与生物制造产业十余年的研究积淀。
王晨晖指出，作为全球领先的投资与企业增长咨询机构，沙利文深耕全球市场65载，扎根中国市场28年，始终紧跟国家战略导向，深度陪伴中国前沿产业成长。立足合成生物与生物制造这一国家战略性新兴赛道，沙利文持续追踪全球技术迭代、产业落地、资本流向与市场变革，深耕产业调研、趋势研判、标杆赋能与资源链接。王晨晖表示，沙利文希望通过本次论坛联动顶尖科研力量、头部产业平台与一线资本资源，搭建高效的产业沟通桥梁，助力行业精准把握政策红利、洞察市场机遇、破解发展瓶颈，未来将持续输出权威行业研究成果，为产业链创新升级、产学研投融合发展持续赋能。在AI时代，沙利文未来也将从一个单一的咨询公司向AI原生结构化知识库的管理者转型，同时诚挚邀请行业领导、教授、头部企业等为中国及全球构建更多纯净安全、公众可信、可溯源、可审计的数据，帮助国家在AI环境下全球范围内抢占更多的话语权。
02
多维论道：共探合成生物学技术创新、治理与产业落地
主题演讲 ：合成生物学赋能生物制造——走向创新链与产业链的深度融合
中国科学院院士 赵国屏先生
在主题演讲环节，中国科学院院士赵国屏先生带来了一场高屋建瓴的主题报告分享。赵院士是分子微生物学家，中国科学院院士、中国医学科学院学术咨询委员会学部委员，发展中国家科学院院士、美国微生物学会会士。现任中国科学院大学杭州高等研究院生命与健康科学学院首席教授，复旦大学生命科学学院微生物组中心主任。研究领域涉及微生物基因组学忆秦娥·娄山关》中"雄关漫道真如铁，而今迈步从头越"的名句，勉励所有与会者——无论是科研人员、企业家还是投资机构在合成生物与生物制造这条前方充满未知与挑战的赛道上，唯有怀抱无畏豪迈的气魄、拥有直面挫折从头再来的勇气，方能跨越重重雄关，抵达产业发展的新高度。主题演讲 ：人工智能与虚拟细胞如何助力生物智造
香港中文大学计算机科学与工程系助理教授 李煜先生香港中文大学计算机科学与工程系助理教授李煜先生分享了题为《人工智能与虚拟细胞如何助力生物智造》的前沿报告。李煜教授2025年入选智源学者，2024年入选《麻省理工科技评论》中国区"35岁以下科技创新35人"，并入选APEC 30岁以下亚太青年领袖，2022年入选福布斯亚洲30岁以下精英榜，是AI与生命科学交叉领域备受瞩目的青年科学家。李煜教授在演讲中系统介绍了其团队围绕"虚拟细胞"构建的核心研究成果。他指出，AI与合成生物学的结合可比拟自然语言处理的发展逻辑——从分子层面的蛋白质与RNA结构预测，到细胞层面的基因表达与药物响应建模，再到多细胞层面的胚胎发育模拟，人工智能正从辅助工具转变为生物制造的"核心引擎"，推动传统合成生物学的"设计-构建-测试-学习"范式向"学习-设计-构建-测试"的新范式跃迁。
03
重磅白皮书即将发布，构筑产业研究基石
沙利文中国高级合伙人兼董事总经理杨晓骋先生与国家生物制造产业创新中心总经理罗巍先生共同上台揭晓，即将于8月中旬发布的《全球及中国合成生物与生物制造产业发展白皮书（2026）》。
杨晓骋表示，沙利文将持续与国家生物制造产业创新中心深化合作，以多层级量度的研究报告为载体，持续跟踪产业发展动态，为行业提供高质量的研究洞察和战略建议。罗巍则表示，国创中心高度重视与沙利文的联合研究合作，未来双方将在产业调研、标准制定、企业孵化等方面展开更深层次的协同。
04
两大战略合作签约，构建产学研用协同生态
论坛期间，沙利文分别与国家生物制造产业创新中心、电子科技大学及复旦大学完成两项重量级战略合作，标志着产业服务平台与国家级创新平台、顶尖高校之间的深度融合迈入新阶段。战略合作仪式1：沙利文 X 国家生物制造产业创新中心沙利文与国家生物制造产业创新中心成立"全球合成生物与生物制造产业研究中心"。双方将立足合成生物与生物制造赛道，围绕技术创新落地、产业生态共建、行业研究赋能、优质项目孵化与成果转化四大核心方向，开展长期、全方位、深层次的战略合作。具体合作内容包括：联合开展行业研究与白皮书编制、共同举办产业论坛与对接活动、搭建产业服务与技术转化一体化赋能平台、助力国内生物制造产业规模化与高质量升级。战略合作仪式2：沙利文 X 电子科技大学 X 复旦大学为进一步整合顶尖高校科研力量、优质人才资源与产业服务平台优势，搭建专属AI*bio产学研协同创新生态，沙利文携手电子科技大学、复旦大学共同开启三方校企战略合作，成立"全球AI*bio研究联盟"。
05
圆桌对话：直面产业痛点，凝聚发展共识
论坛设置两场高质量的圆桌对话，分别聚焦产业投资挑战与AI融合发展议题，为与会者带来了多维度的思想碰撞。
圆桌对话1：生物制造产业投资的挑战和应对
第一场圆桌讨论以"生物制造产业投资的挑战和应对"为主题。由合成生物学媒体"转化子"创始人李诗渊博士主持，他同时也是《合成生物：生命的编程艺术》的编著者，博士毕业于中国科学院上海生命科学研究院，在合成生物学领域兼具学术深度与产业洞察经验。
圆桌对话2：AI时代浪潮下，生物制造产业的发展及挑战
第二场圆桌以"AI时代浪潮下，生物制造产业的发展及挑战"为主题，由中国科学院深圳先进技术研究院合成生物学研究所副所长、合成微生物组学研究中心主任戴磊研究员主持。戴磊是国家重点研发计划青年项目首席科学家、国家级青年人才，入选《麻省理工科技评论》中国区"35岁以下科技创新35人"，其实验室致力于利用合成生物学工具对微生物组结构和功能进行理性设计和精准调控，解决人体健康、农业生产等重大问题。
圆桌讨论2：AI时代浪潮下，生物制造产业的发展及挑战
从左至右：合成生物学媒体"转化子"创始人、中科创星研究员李诗渊博士；帝斯曼芬美意创新负责人王冰清女士；上海羽冠生物技术有限公司创始人兼首席执行官林秋彬博士；华熙元祐基金合伙人兼华熙唐安生物顾问梁爽博士；苏州聚维元创生物科技有限公司联合创始人兼首席技术官李承博士；道生生物联合创始人兼首席运营官袁林博士。
从左至右：电子科技大学人文社科高等研究院教授、副院长雷瑞鹏女士；复旦大学国际关系与公共事务学院教授、博士生导师唐莉女士（学生代表出席）；电子科技大学人文社科高等研究院教授、副院长雷瑞鹏女士；沙利文中国高级合伙人兼董事总经理杨晓骋先生。
从左至右：联想创投集团董事张强先生；杭州恩和生物科技有限公司副总裁朱洁女士；艾比欧义（杭州）生物科技有限公司创始人兼首席执行官刘大鹏先生。
Professor Lei’s main research areas include life science philosophy, bioethics, and ethical governance of emerging technology. She has led several national-level projects such as the National Key R&D Program and major projects under the National Social Science Fund. She has published over ten books and more than 100 papers. In 2019, she published the first policy commentary article in the domestic humanities field in Nature: “Reboot Ethics Governance in China.” Here, she first introduced the concepts of “ethical governance of technology” and “ethics first” in China, and systematically explained the basic principles of ethical governance of technology. These concepts and principles have been adopted in a series of central documents and the Opinions of the State Council on Strengthening Ethical Governance of Technology. In her speech, Professor Lei pointed out that AI technology has accelerated the innovation pace of synthetic biology, but it also brings unprecedented ethical challenges and governance difficulties. She stated that sustainable innovation is essential for long-term success, and comprehensive ethical guidelines and modern governance systems are crucial for the sustainable development of the synthetic biology industry. From multiple perspectives including the development trends of Al*Bio technology, ethical governance, and regulatory policies, she systematically explained how to establish an ethical governance framework compatible with technological innovation, providing profound insights for all practitioners and highlighting the baseline and direction for the healthy development of the industry.
Keynote Speech: The Application Prospects of Engineering Phages
Dr. Tan Xin, General Manager of Zhongke Xinfly (Shenzhen) Biotechnology Co., Ltd.
Dr. Tan Xin, General Manager of Zhongke Xinfly (Shenzhen) Biotechnology Co., Ltd., presented a special talk on “The Application Prospects of Engineering Phages”.
With extensive experience in clinical medicine and phage research, Dr. Tan Xin has led nearly 60 clinical applications of phage therapy, possessing systematic expertise from patient screening, phage matching, treatment plan design, to efficacy and safety evaluation. He has presided over multiple projects funded by the National Natural Science Foundation, and joined Zhongke Xinfly as a co-founder in 2025. In his speech, Dr. Tan Xin systematically discussed the potential of engineering phages in various fields such as biomedicine, modern agriculture, and environmental ecology. He focused on the company’s successful treatment of multiple severe drug-resistant infections using personalized phage treatment plans, as well as the progress in developing generic new drugs. Additionally, he mentioned the application of engineering phages in animal health, serving as a green “substitute for antibiotics” solution for livestock, poultry, and aquaculture, effectively addressing antibiotic abuse and bacterial resistance in animal husbandry. Dr. Tan Xin noted that phage therapy, as an important application of synthetic biology in the field of microbial group engineering, is gradually moving from the laboratory to clinical and industrial applications, showing broad commercial prospects.
03
A Major White Paper Will Be Released, Establishing a Foundation for Industry Research
Mr. Yang Xiaocheng, Senior Partner and Managing Director of Frost & Sullivan China, and Mr. Luo Wei, General Manager of the National Bio Manufacturing Industry Innovation Center, jointly unveiled the upcoming Global and China Synthetic Biology and Bio Manufacturing Industry Development White Paper (2026) to be released in mid-August.
Yang Xiaocheng said that Frost & Sullivan will continue to deepen cooperation with the National Bio Manufacturing Industry Innovation Center, using multi-level research reports as a medium to continuously track industry developments and provide high-quality research insights and strategic recommendations to the industry. Luo Wei expressed that the Innovation Center values its joint research with Frost & Sullivan, and in the future, both parties will collaborate more deeply in industry research, standard setting, and enterprise incubation.
Mr. Yang Xiaocheng, Senior Partner and Managing Director of Frost & Sullivan China
Additionally, representatives of companies selected for the white paper also witnessed the upcoming release of this research achievement. The participating companies cover upstream biologic equipment manufacturing and downstream core sectors such as biomedicine and consumer goods. The successful preparation and implementation of this white paper also bring together professional expertise from industry platforms, academic think tanks, capital institutions, and industry associations. From the perspectives of industry practice, technology implementation, and product commercialization, it provides a solid foundation for the white paper.
Representatives of companies collaborating on the white paper: Jiangsu Meishangjie Biotech Co., Ltd., Jiangsu Jiewei Biological Equipment Co., Ltd., Jiangsu Jiansan Biotech Co., Ltd., Shanghai Shenghezhiu Biotech Co., Ltd., Anjiyi Industrial (Shanghai) Co., Ltd., Shanghai Daoyu Biotech Co., Ltd., Huisile Health Technology (Shanghai) Co., Ltd. (unordered list)
Meanwhile, Ms. Sun Rong, Consulting Director of Frost & Sullivan China, as the main person in charge and author of the Global and China Synthetic Biology and Bio Manufacturing Industry Development White Paper (2026), provided an early interpretation of the core content of the report.
Sun Rong pointed out that this white paper continues the 2025 release of the Shanghai Synthetic Biology and Bio Manufacturing Industry Development White Paper (2025). The writing process follows Frost & Sullivan’s professional standards in industry research, relying on the collaborative research framework of “government, industry, academia, research, finance, application, and service”. It integrates resources, insights, and empirical cases from key entities at all levels of the industry chain, representing a collaborative achievement of the entire industry. The Frost & Sullivan research team analyzed industrial policies, innovation ecosystems, and cluster development models in various countries around the world, compared with the development paths of leading enterprises and innovation platforms at home and abroad, and systematically summarized the common patterns and regional differences in global industry development. By combining China’s industrial research advantages, platform construction status, and industrialization characteristics, it deeply explored industry resources, development challenges, and core competitive advantages, taking into account the global macro environment and China’s micro practices, ensuring a comprehensive, objective, and practical research perspective. The core goal of this report is to provide government agencies, investment institutions, the industry, research institutions, and all sectors of society with comprehensive, objective, professional, and implementable insights and decision-making references for industry development.
04
Two Major Strategic Partnerships Signed to Build a Collaborative Ecosystem of Industry, Academia, Research, and Application
During the forum, Frost & Sullivan signed two significant strategic partnerships with the National Bio Manufacturing Industry Innovation Center, University of Electronic Science and Technology of China, and Fudan University, marking a new stage in the deep integration between industry service platforms, national-level innovation platforms, and top universities.
Strategic Partnership Ceremony 1: Frost & Sullivan X National Bio Manufacturing Industry Innovation Center
Frost & Sullivan and the National Bio Manufacturing Industry Innovation Center established the “Global Synthetic Biology and Bio Manufacturing Industry Research Center”. Both parties will focus on synthetic biology and bio manufacturing, conducting long-term, comprehensive, and deep strategic cooperation in four core areas: technological innovation implementation, industry ecosystem building, industry research empowerment, and high-quality project incubation and transformation. Specific cooperation includes: jointly conducting industry research and white paper compilation, co-organizing industry forums and matchmaking activities, establishing an integrated service and technology transformation enabling platform, and helping to scale up and improve the quality of the domestic bio manufacturing industry.
Mr. Yang Xiaocheng, Senior Partner and Managing Director of Frost & Sullivan China, and Mr. Luo Wei, General Manager of the National Bio Manufacturing Industry Innovation Center, as representatives of both parties, stepped onto the stage to unveil the white paper and take a photo. Yang Xiaocheng said that the strong collaboration between Frost & Sullivan and the National Bio Manufacturing Industry Innovation Center will enable efficient communication between industry research and platform resources. He looks forward to more industry collaborative projects being implemented in the future to jointly promote the thriving development of the domestic bio manufacturing industry.
From left to right: Mr. Yang Xiaocheng, Senior Partner and Managing Director of Frost & Sullivan China; Mr. Luo Wei, General Manager of the National Biomanufacturing Industry Innovation Center.
Strategic Cooperation Ceremony 2: Frost & Sullivan X University of Electronic Science and Technology X Fudan University
In order to further integrate top university research capabilities, high-quality talent resources, and industrial service platform advantages, and establish a dedicated AI*bio industry-academia-research collaborative innovation ecosystem, Frost & Sullivan, in collaboration with University of Electronic Science and Technology and Fudan University, launches a tripartite school-industry cooperation initiative to form the "Global AI*bio Research Alliance".
From left to right: Ms. Tang Li, Professor and Doctoral Supervisor at the School of International Relations and Public Affairs, Fudan University (attended by student representatives); Ms. Lei Ruipeng, Professor and Deputy Dean at the Institute of Humanities and Social Sciences, University of Electronic Science and Technology; Mr. Yang Xiaocheng, Senior Partner and Managing Director of Frost & Sullivan China.
The three parties will focus on core areas such as the ethical governance system for the integration of cutting-edge innovation chains and industrial chains in AI and biotechnology, the policy ecosystem for the industrial implementation of scientific and technological achievements, joint training of professionals, and exploration of industry innovation applications. Together, they will address technical bottlenecks and industrial challenges in AI-driven biomanufacturing, achieving mutual empowerment and complementary strengths between schools and industries. This school-industry cooperation will break down barriers between academic research and industrial markets, creating a complete innovation chain from technology development, talent cultivation to industrial implementation, providing strong support for continuous innovation in the AI-enabled synthetic biology industry.
05
Roundtable Discussion: Addressing Industrial Challenges and Building Development Consensus
The forum features two high-quality roundtable discussions, focusing on industrial investment challenges and AI integration development, offering diverse perspectives for participants.
Roundtable Discussion 1: Investment Challenges and Solutions in Biomanufacturing Industry
The first roundtable discussion is titled "Investment Challenges and Solutions in Biomanufacturing Industry." Hosted by Dr. Li Shiyuan, founder of the synthetic biology media "Transformer," who is also the author of "Synthetic Biology: The Art of Life Programming." He graduated from the Shanghai Institute of Life Sciences, Chinese Academy of Sciences, and brings academic depth and industry insights in synthetic biology.
From left to right: Dr. Li Shiyuan, Founder of synthetic biology media "Transformer" and researcher at CIC Star; Ms. Wang Bingqing, Head of Innovation at DSM Fine & Specialty; Dr. Lin Qiubin, Founder and CEO of Shanghai Yuguan Biotechnology Co., Ltd.; Dr. Liang Shuang, Partner and Biostar Tang An Biological Advisor at Huaxi Yuanyou Fund; Dr. Li Cheng, Co-founder and Chief Technology Officer of Suzhou Juyuan Yuanchuang Biotechnology Co., Ltd.; Dr. Yuan Lin, Co-founder and Chief Operations Officer of Daosheng Biology.
During the discussion, the guests engaged in in-depth conversations on investment logic and industrial empowerment under the context of long-term projects and high R&D investment in synthetic biology. Ms. Wang Bingqing shared DSM Fine & Specialty’s open innovation strategy and external cooperation experience in biotechnology from the perspective of an international enterprise innovation leader. Dr. Lin Qiubin discussed how startups balance R&D investment and cash flow management during the technology validation phase based on Yuguan Biotechnology’s practices in synthetic vaccines and microbial modification. Dr. Liang Shuang analyzed Huaxi Biology’s strategic layout in synthetic biology from the perspective of industrial capital, emphasizing that industrial capital values the synergy between technology and existing business systems more than financial returns. Dr. Li Cheng introduced Juyuan Yuanchuang’s technological breakthroughs in straw-based biomanufacturing, highlighting the importance of non-grain biomass utilization for sustainable green development in synthetic biology. Dr. Yuan Lin shared Daosheng Biology’s experiences and lessons in the industrialization of synthetic natural pigments, stressing that process scaling and cost control are key to making technologies commercially viable. The guests agreed that investment in synthetic biology requires investment institutions to have specialized technical expertise and patient capital characteristics, and also needs government, industry, and research institutions to jointly build a more comprehensive pilot platform, regulatory standards, and market access system.
Roundtable Discussion 2: Development and Challenges of Biomanufacturing Industry in the AI Era
The second roundtable, titled "Development and Challenges of Biomanufacturing Industry in the AI Era," is hosted by Dr. Dai Lei, Deputy Director of the Synthetic Biology Institute at Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, and Director of the Synthetic Microbiome Research Center. Dr. Dai is a chief scientist in a national key research project, a national young talent, and was listed in the "35 Under 35" list by MIT Technology Review China. His laboratory focuses on rational design and precise regulation of microbial genome structure and function using synthetic biology tools to address issues in human health and agricultural production.
From left to right: Dr. Dai Lei, Deputy Director of the Synthetic Biology Institute at Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, and Director of the Synthetic Microbiome Research Center; Ms. Tang Menghua, Director, Secretary of Board, and Deputy General Manager of Shanxi Jinbo Biopharmaceutical Co., Ltd.; Ms. Wang Jun, Secretary of Board and General Counsel of InSilicon Intelligence Technology (Shanghai) Co., Ltd.; Mr. Zhang Qiang, Director of Lenovo Venture Capital Group; Ms. Zhu Jie, Vice President of Hangzhou EnBio Technology Co., Ltd.; Mr. Liu Dapeng, Founder and CEO of Aibioyi (Hangzhou) Biotech Co., Ltd.
This panel discussion provided a comprehensive and in-depth analysis of topics such as practical implementation paths, technical barriers, commercialization challenges, and compliance risks in AI-driven biomanufacturing. Ms. Tang Menghua shared Frost & Sullivan China’s experience in AI-assisted protein design, highlighting how AI significantly enhances the efficiency of developing biocompatible materials like human-derived collagen. However, clinical validation and market acceptance of final products remain critical factors. Ms. Wang Jun, from the perspective of compliance in AI pharmaceutical companies, examined legal issues related to intellectual property protection, data security, and regulatory approvals in the context of generative AI in drug development, emphasizing the need for balanced approaches between technological innovation and compliance management. Mr. Zhang Qiang, from an investment perspective, presented Lenovo Venture Capital’s investment strategy in AI4S and biomanufacturing, noting that current bottlenecks are shifting from AI generation to wet lab validation and iteration. Differentiated competitiveness will be achieved through scenario understanding, accumulated process know-how, and private data generated by proprietary automation platforms. Ms. Zhu Jie, based on Enhe Technology’s practices in AI-driven biomanufacturing, explained how Physical AI integrates the entire process from AI design and automated experiments to large-scale production, helping AI4S transition from a research tool to a real-world application and enhancing the industrial delivery capabilities of biomanufacturing. As the founder of an AI×BIO startup, Mr. Liu Dapeng shared the company’s technological advancements in using AI algorithms and cell models to predict target gene targets and improve desired products, as well as the practical challenges faced by startups in applying advanced technologies to industrial settings to boost efficiency and achieve value creation. Director Dai Lei concluded that the deep integration of AI and synthetic biology is reshaping the industry’s research paradigm. The key to successful implementation lies in creating irreplaceable real value in specific applications, which requires continuous collaboration among academia, industry, and investment sectors.
06
Starting from a new beginning, heading towards a new future together
This special forum on synthetic biology and biomanufacturing offered a high-level, in-depth, and multi-faceted intellectual exchange for the industry. We had the opportunity to hear profound insights from Academician Zhao Guoping, based on the fundamentals of the discipline and national strategies, as well as his expectations for peers. Additionally, we received cutting-edge knowledge sharing from scholars from domestic and international universities and industry experts on topics such as AI integration with biology and ethical governance systems. High-quality panel discussions were also held on core issues including AI-biomass integration, industrial implementation challenges, commercialization pathways, and industry compliance governance. Meanwhile, Frost & Sullivan has established two significant strategic partnerships with the National Biomanufacturing Industry Innovation Center, University of Electronic Science and Technology of China, and Fudan University, initiating a collaborative innovation ecosystem in synthetic biology and biomanufacturing, as well as AI*bio.
Currently, synthetic biology and biomanufacturing are at the core of the global technological revolution and industrial transformation. Leveraging Frost & Sullivan’s 65 years of global industry research experience and 28 years of expertise in China, we will continue to collaborate with national industry platforms, top universities, leading research institutions, industry leaders, and investment firms. We aim to provide authoritative industry research, establish a deep integration platform for industry, academia, research, investment, and services, support technological innovation and the growth of high-quality enterprises, and enhance the industrial ecosystem, helping China’s synthetic biology and biomanufacturing industry progress steadily and develop sustainably.
